<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00700115</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00006876</org_study_id>
    <secondary_id>KITE-6876</secondary_id>
    <nct_id>NCT00700115</nct_id>
  </id_info>
  <brief_title>Kaletra-isentress Treatment Evaluation</brief_title>
  <acronym>KITE</acronym>
  <official_title>A Pilot Study to Assess the Safety, Efficacy, and PK Profile of a Switch in Antiretroviral Therapy to a RTI Sparing Combination of LPV/r and RAL in Virologically Suppressed HIV-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effectiveness and safety of raltegravir (isentress) when used
      together with lopinavir/ritonavir (kaletra) for the treatment of HIV-infection. Isentress is
      a recently, Food and Drug Administration (FDA) approved, HIV medication that has strong
      effects against the HIV virus. Isentress has been shown in other studies to be safe and well
      tolerated by HIV patients. Combining this drug with kaletra might enable us to construct a
      HIV regimen that does not include the more toxic drugs of the nucleoside reverse
      transcriptase inhibitor class.

      Eligible volunteers will undergo the following as part of the study procedure:

        1. Sign the study consent form and the HIPAA Authorization Form.

        2. Two-third of subjects, the intervention group (selected by random chance) will have
           their HIV drug treatment changed to kaletra + isentress.

        3. The other one-third will continue their usual HIV medications (this will be the control
           group).

        4. Make 9 study related visits to the Ponce clinic during the 48 weeks study period. During
           these visits, medical information will be collected, and blood tests will be performed.

        5. Perform Dexa-scan on two separate occasions at Emory University Hospital Radiology.

      Information collected will be used to assess the effectiveness of this treatment in keeping
      the HIV virus suppressed, how well these two drugs together is tolerated by HIV-infected
      patients, and the blood levels of these two drugs when given together.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RATIONALE: Virologic failure and adverse effects associated with current highly active
      antiretroviral therapy (HAART) warrant continuing search for novel combination therapeutic
      options. Raltegravir's (RAL) was recently shown to be a potent antiretroviral (ARV) agent
      with a favorable safety profile. If future reports continue to show positive data on this
      first-in-class integrase inhibitor, there may be a paradigm shift in the currently
      recommended first line HAART to regimens that will include integrase inhibitors.

      Combining RAL with a drug that has a high genetic barrier to resistance, such as
      lopinavir/ritonavir (LPV/r) may offer a number of advantages. Both agents are potent and
      should produce durable virologic suppression. Because their combination is reverse
      transcriptase inhibitor (RTI) class sparing, its tolerability might be superior. In addition,
      RAL is not metabolized by the cytochrome P-450 enzymes, therefore, a compatible
      pharmacokinetic profile is expected with this combination. Pairing LPV/r with RAL in early
      ARV regimens as is proposed in this application may provide a HAART regimen that is highly
      efficacious and durable, with less resistance and adverse drug events.

      DESIGN: This is single center, open label, randomized, controlled, study designed to assess
      the tolerability, pharmacokinetic compatibility, and the durability of virologic suppression
      of the RTI sparing combination therapy of LPV/r + RAL. HIV-infected subjects who are
      virologically suppressed (HIV-RNA PCR &lt; 50 copies/ml) on current HAART regimen will be
      randomized in a 2:1 fashion to be switched to a regimen consisting of LPV/r + RAL,
      intervention arm A (n=40), or to be continued on their pre-study HAART regimen, control arm B
      (n=20). The primary endpoint will be proportion of subjects with sustained virologic
      suppression (HIV-1 RNA PCR &lt; 50 copies/ml) through week 48. The immunoreconstitution,
      toxicity profile, and pharmacokinetic profile of the RAL and LPV/r in this novel combination
      therapy will be evaluated.

      DURATION: 48 weeks after the enrollment of the last participant. Enrollment is expected to
      take about 10 months.

      SAMPLE SIZE: 60 subjects.

      POPULATION: HIV-infected individuals (male and female), Age &gt; 18 years, who are virologically
      suppressed (HIV-RNA PCR &lt; 50 copies/ml) on their current HAART regimen for &gt; 6 months.

      REGIMEN: For Arm A= LPV/r 400/100 mg (2 tablets) twice daily + RAL 400 mg (1 tablet) twice
      daily taken by mouth. For Arm B=Pre-study HAART regimen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Viral Loads (HIV-1 RNA PCR)</measure>
    <time_frame>baseline to week 48</time_frame>
    <description>Percentage subjects with undetectable Plasma viral loads</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Compare Plasma Triglyceride Levels at 48 Weeks Between LPV/r + RAL and Standard HAART Treated Subjects</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Kaletra + Isentress</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kaletra + Isentress</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard HAART</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-study Antiretroviral regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kaletra + Isentress</intervention_name>
    <description>Kaletra 400/100 mg + Isentress 400 mg BID</description>
    <arm_group_label>Kaletra + Isentress</arm_group_label>
    <other_name>Raltegravir</other_name>
    <other_name>Lopinavir/ritonavir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pre-study antiretroviral regimen</intervention_name>
    <description>Standard doses of pre-study antiretroviral regimen</description>
    <arm_group_label>Standard HAART</arm_group_label>
    <other_name>HAART</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1-infected individuals receiving HAART regimen (if on PI-based regimen, must be
             1st PI-containing HAART).

          -  They must have been on and tolerating current HAART regimen for &gt; 6-months.

          -  Plasma HIV-1 viral load &lt; 50 copies/ml at study entry.

          -  Men and women age &gt; 18 years (sex is defined as sex at birth).

          -  Laboratory values obtained within 30 days prior to study entry:

               -  Hemoglobin &gt; 9.4 g/dl

               -  Creatinine &lt; 2 mg/dl

               -  AST (SGOT) &lt; 2 x ULN

               -  ALT (SGPT) &lt; 2 x ULN

          -  Ability and willingness of subject or legal guardian/representative to give written
             informed consent.

          -  No CD4 T-cell counts requirement

        Exclusion Criteria:

          -  Subjects with a history of previous intolerance to or virological failure to LPV/r

          -  Concomitant drugs (including alternative therapies) that may affect PI or RAL plasma
             concentrations (inducers or inhibitors of the CYP 3A4 or UDP-glucuronosyltransferase
             iso-enzymes).

          -  A known history of noncompliance with medications or a known history of noncompliance
             with scheduled physician and clinic visits.

          -  Investigational ARV drug.

          -  Pregnancy/Breast feeding.

          -  HBV-coinfected patients receiving nucleoside analogue for both HIV and HBV
             suppression.

          -  Active drug or alcohol use or dependence which, in the Investigator's opinion, may
             interfere with adherence to study requirements or endanger subject's health while on
             the study.

          -  Serious illness requiring systemic treatment and/or hospitalization within 30 days
             prior to the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igho Ofotokun, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Infectious Diseases Program (Ponce Clinic)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ofotokun I, Sheth AN, Sanford SE, Easley KA, Shenvi N, White K, Eaton ME, Del Rio C, Lennox JL. A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study. AIDS Res Hum Retroviruses. 2012 Oct;28(10):1196-206. Epub 2012 Apr 20.</citation>
    <PMID>22364141</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2008</study_first_submitted>
  <study_first_submitted_qc>June 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2008</study_first_posted>
  <results_first_submitted>June 7, 2012</results_first_submitted>
  <results_first_submitted_qc>August 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 22, 2013</results_first_posted>
  <last_update_submitted>November 25, 2014</last_update_submitted>
  <last_update_submitted_qc>November 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Ighovwerha Ofotokun</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>HAART</keyword>
  <keyword>lopinavir/ritonavir</keyword>
  <keyword>raltegravir</keyword>
  <keyword>HIV/AIDS patients on HAART</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All subjects were recruited from an urban outpatient HIV clinic (the Grady Infectious Diseases Program Out-patient Clinic, Atlanta, Georgia) between June 2008 and January 2011.</recruitment_details>
      <pre_assignment_details>Subjects were excluded if they were on medications that could interact with Protease inhibitors, had an active opportunistic infection, had renal and/or hepatic impairment, or were pregnant. Hepatitis B virus (HBV) co-infected patients receiving a nucleotide analogue for both HIV and HBV suppression were also excluded from enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Kaletra + Isentress</title>
          <description>Switched to Kaletra + Isentress</description>
        </group>
        <group group_id="P2">
          <title>Standard HAART</title>
          <description>Pre-study standard HAART regimen</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Kaletra + Isentress</title>
          <description>switched to Kaletra + Isentress</description>
        </group>
        <group group_id="B2">
          <title>Standard HAART</title>
          <description>Pre-study standard HAART regimen</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="9"/>
                    <measurement group_id="B2" value="48" spread="12"/>
                    <measurement group_id="B3" value="47" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>To Compare Plasma Triglyceride Levels at 48 Weeks Between LPV/r + RAL and Standard HAART Treated Subjects</title>
        <time_frame>48 weeks</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Kaletra + Isentress</title>
            <description>switched to Kaletra + Isentress</description>
          </group>
          <group group_id="O2">
            <title>Standard HAART</title>
            <description>Pre-study standard HAART regimen</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare Plasma Triglyceride Levels at 48 Weeks Between LPV/r + RAL and Standard HAART Treated Subjects</title>
          <population>intention to treat</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238.1" spread="19.9"/>
                    <measurement group_id="O2" value="133.3" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Viral Loads (HIV-1 RNA PCR)</title>
        <description>Percentage subjects with undetectable Plasma viral loads</description>
        <time_frame>baseline to week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Kaletra + Isentress</title>
            <description>switched to Kaletra + Isentress</description>
          </group>
          <group group_id="O2">
            <title>Standard HAART</title>
            <description>Pre-study standard HAART regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Viral Loads (HIV-1 RNA PCR)</title>
          <description>Percentage subjects with undetectable Plasma viral loads</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" lower_limit="83" upper_limit="100"/>
                    <measurement group_id="O2" value="88" lower_limit="75" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Kaletra + Isentress</title>
          <description>switched to Kaletra + Isentress</description>
        </group>
        <group group_id="E2">
          <title>Standard HAART</title>
          <description>Pre-study standard HAART regimen</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The findings of the KITE study should be interpreted in the context of a pilot study with a small sample size. Furthermore, adverse effects were self-reported, and the lack of blinding may have introduced biases in the collection of the data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Igho Ofotokun</name_or_title>
      <organization>Emory University School of Medicine</organization>
      <phone>404-616-0659</phone>
      <email>iofotok@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

